智通财经APP讯,康宁杰瑞制药-B(09966)公布2024年业绩,收入约6.4亿元,同比增长192.58%;年内溢利约1.66亿元,同比扭亏为盈;每股盈利0.17元。
期内,许可费收入(于某一时间点确认)为4.64亿元(2023年:720万元)。大幅增加主要由于公司于截至2024 年12月31日止年度订立的合作及许可协议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.